TP53 and cancer: If true, this model predicts that estrogen reduction or withdrawal from G-allele MDM2 SNP309 patients could be incorporated in prevention strategies for p53-germlinc carriers, for whom cancer prevention strategies are limited, much as they have been successfully implemented for BRCA-mutation carriers [35]-[37].